IniXium is a division of NuChem Sciences, a contractual research team that directly targets the structural biology needs of the pharmaceutical and biotech industry to support their discovery workflow. We are experts in protein chemistry, protein crystallization and X-ray structure determination. We offer gene to structure services as well as fragment screening, and co-structure determination to support the optimization of your lead compounds. Since August 2023, NuChem and its divisions OmegaChem & IniXium are now part of the Sygnature Discovery group.
